The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

NCT04984369 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Shanghai Henlius Biotech